T1 -异烟肼或利福平治疗潜伏性结核感染:以人群为基础的研究肝毒性、完成和成本JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02048 -2019欧元SP - 1902048 AU -罗纳德,丽莎·a . AU -菲茨杰拉德,J .马克AU - Bartlett-Esquilant Gillian AU -舒瓦,Kevin AU -贝内代蒂,安德里亚盟——Boivin,让非盟-孟N2 -背景临床试验表明，4个月利福平(4R)较9个月异烟肼(9H)治疗潜伏性结核感染(LTBI)肝毒性更低，依从性更好。我们的目标是比较严重的肝脏不良事件和治疗完成的频率，以及LTBI方案4R和9H在加拿大魁北克省的一般人口中的直接卫生系统成本，使用省卫生行政数据。方法:我们的回顾性队列研究包括2003年至2007年间所有开始使用利福平或异烟肼治疗的患者。我们评估了来自住院记录的肝毒性，来自社区药房记录的治疗完成情况，以及来自账单记录和费用计划表的直接成本。我们使用logistic(肝毒性)、log-二项(完成)和gamma(成本)回归分析比较利福平和异烟肼，并根据年龄、共病和其他混杂因素进行调整。结果10559人开始LTBI治疗(9684异烟肼;875利福平)。利福平患者年龄较大，基线共病较多。异烟肼(n=15)的严重肝毒性风险高于利福平(n=1)，校正OR=2.3 (95%CI: 0.3,16.1);肝移植2例，异烟肼1例，利福平1例。 Overall, patients without co-morbidities had lower hepatotoxicity risk (0.1% versus 1.0%). 4R completion (53.5%) was higher than 9H (36.9%), adjusted RR=1.5 (95%CI:1.3,1.7). Mean costs per patient were lower for rifampin than isoniazid: adjusted Cost Ratio=0.7 (95%CI:0.5,0.9).Conclusion Risk of severe hepatotoxicity and direct costs were lower, and completion was higher, for 4R than 9H, after adjustment for age and co-morbidities. Severe hepatotoxicity resulted in death or liver transplant in three patients receiving 9H, compared to no patients receiving 4R.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Ronald has nothing to disclose.Conflict of interest: Dr. Fitzgerald has nothing to disclose.Conflict of interest: Dr. Bartlett-Esquilant has nothing to disclose.Conflict of interest: Dr. Schwartzman has nothing to disclose.Conflict of interest: Dr. Benedetti has nothing to disclose.Conflict of interest: Dr. Boivin has nothing to disclose.Conflict of interest: Dr. Menzies has nothing to disclose. ER -